Full-spectrum endoscopy improves surveillance for dysplasia in patients with inflammatory bowel diseases

Rupert W. Leong, Marie Ooi, Crispin Corte, Yunki Y. Yau, Melissa Kermeen, Peter H. Katelaris, Charles McDonald, Meng Chong Ngu

Research output: Contribution to journalArticlepeer-review

25 Citations (Scopus)


Background & Aims Inflammatory bowel diseases (IBDs) increase the risk of colorectal cancer. Surveillance colonoscopy with chromoendoscopy is recommended, but conventional forward-viewing colonoscopy (FVC) detects dysplasia with low levels of sensitivity. Full-spectrum endoscopy (FUSE) incorporates 2 additional lateral cameras to the forward camera of the colonoscope, allowing endoscopists to view behind folds and in blind spots, which might increase dysplasia detection. We compared FUSE vs FVC in the detection of dysplasia in patients with IBDs. Methods We performed a prospective, randomized, cross-over, tandem colonoscopy study comparing FVC vs FUSE in 52 subjects with IBD undergoing surveillance for neoplasia in Australia (23 with Crohn's colitis, 29 with ulcerative colitis; median age, 45.0 y; 60% male; mean IBD duration, 16.4 y). All subjects met national IBD surveillance inclusion criteria; 27 were assigned randomly to groups that underwent FVC followed by FUSE, and 25 were assigned to groups that underwent FUSE followed by FVC. All procedures were performed from February 2014 through December 2015. Random biopsy specimens were collected and visible lesions were collected; all were analyzed histologically. The primary end point was dysplasia missed by the first colonoscopy detected by the second colonoscopy. Dysplasia was diagnosed by an expert gastrointestinal pathologist blinded to the colonoscope allocation in consensus with a second expert pathologist. Results FVC missed 71.4% of dysplastic lesions per lesion whereas FUSE missed 25.0% per lesion (P =.0001); FVC missed 75.0% of dysplastic lesions per subject and FUSE missed 25.0% per subject (P =.046). FUSE identified a mean of 0.37 dysplastic lesions and FVC identified a mean of 0.13 dysplastic lesions (P =.044). The total colonoscopy times were similar (21.2 min for FUSE vs 19.1 min for FVC; P =.32), but withdrawal time was significantly longer for FUSE (15.8 min) than for FVC (12.0 min) (P =.03). Correcting for per-unit withdrawal time, the mean dysplasia miss rate per subject was significantly lower for FUSE (0.19) than for FVC (0.83; P < .0001). Targeted tissue acquisition identified significantly more dysplastic lesions than random biopsies (P <.0001). Conclusions In a prospective cross-over study of IBD patients undergoing surveillance colonoscopy, we found panoramic views obtained by full-spectrum endoscopy increased the number of dysplastic lesions detected, compared with conventional forward-viewing colonoscopy. Trial no: ACTRN12616000047493.

Original languageEnglish
Pages (from-to)1337-1344
Number of pages11
Issue number6
Early online date23 Jan 2017
Publication statusPublished - May 2017
Externally publishedYes


  • FUSION study
  • colon cancer
  • neoplasm
  • Crohn's disease
  • Neoplasm
  • Crohn's Disease
  • Colon Cancer
  • FUSION Study


Dive into the research topics of 'Full-spectrum endoscopy improves surveillance for dysplasia in patients with inflammatory bowel diseases'. Together they form a unique fingerprint.

Cite this